These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 17852138

  • 1. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation.
    Sitruk-Ware R.
    Climacteric; 2007 Oct; 10(5):358-70. PubMed ID: 17852138
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Parenteral administration of progestins for hormonal replacement therapy.
    Nath A, Sitruk-Ware R.
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):88-96. PubMed ID: 19340703
    [Abstract] [Full Text] [Related]

  • 5. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.
    Du Y, Scheidt-Nave C, Schaffrath Rosario A, Ellert U, Dören M, Knopf H.
    Climacteric; 2009 Aug; 12(4):329-40. PubMed ID: 19437194
    [Abstract] [Full Text] [Related]

  • 6. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TREAT.
    Maturitas; 2005 Sep 16; 52(1):1-10. PubMed ID: 15963666
    [Abstract] [Full Text] [Related]

  • 7. Menopausal hormone replacement therapy.
    Varner RE.
    Curr Womens Health Rep; 2003 Oct 16; 3(5):410-7. PubMed ID: 12959701
    [Abstract] [Full Text] [Related]

  • 8. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP.
    J Fam Pract; 2004 Jul 16; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract] [Full Text] [Related]

  • 9. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E, Canfell K.
    Am J Epidemiol; 2009 Jul 01; 170(1):24-8. PubMed ID: 19468078
    [Abstract] [Full Text] [Related]

  • 10. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
    Lobo RA.
    Climacteric; 2007 Oct 01; 10 Suppl 2():21-6. PubMed ID: 17882668
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M, Simoncini T, Fuller S, Genazzani AR.
    Maturitas; 2008 Oct 01; 60(3-4):185-201. PubMed ID: 18775609
    [Abstract] [Full Text] [Related]

  • 13. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertüngealp J, Gompel A, Graziottin A, Hudita D, Pines A, Rozenberg S, Samsioe G, Stevenson JC, European Menopause and Andropause Society.
    Maturitas; 2005 May 16; 51(1):8-14. PubMed ID: 15883103
    [Abstract] [Full Text] [Related]

  • 14. Progestins in HRT: sufferance or desire?
    Skouby SO, Jespersen J.
    Maturitas; 2009 Apr 20; 62(4):371-5. PubMed ID: 19203850
    [Abstract] [Full Text] [Related]

  • 15. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.
    Stefanick ML.
    Am J Med; 2005 Dec 19; 118 Suppl 12B():64-73. PubMed ID: 16414329
    [Abstract] [Full Text] [Related]

  • 16. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA.
    Climacteric; 2007 Oct 19; 10 Suppl 2():27-31. PubMed ID: 17882669
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK, Governale LA.
    Pharmacoepidemiol Drug Saf; 2005 Mar 19; 14(3):171-6. PubMed ID: 15386701
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.